EU의 제약산업에 대한 경쟁법 집행 및 경쟁정책과 그 시사점
Review of EU Competition Law Enforcement, Competition Policy on the Pharmaceutical Industry and Implications
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Europe, together with United States, has led the growth of the pharmaceutical industry around the world. However, some criticized that principle of competition did not work well due to the structural and regulatory characteristics of the pharmaceutical industry. In 2009, the EU Commission conducted sector inquiry on the pharmaceutical industry and reviewed various legal issues in the perspective of the EU competition rules. After the sector inquiry, EU competition authorities have actively enforced their competition rules on the pharmaceutical industry and have actively prepared and implemented competition policies for the industry. Finally, at the request of the EU Parliament and the EU Council, the EU Commission recently submitted a report which includes representative cases and relevant statistics of EU competition authorities on the pharmaceutical industry. Because the industry size is very large and lots of dominant companies have been existed, violations of competition rules have been occurred in various forms and ways. In the perspective of comparative law and comparative administration, it is highly valuable to research about how the EU competition rules, which has played a major role in the global competition law with the United States, has addressed the behaviors. However, since the KFTC published the competition policy report on pharmaceutical industry in 2009, there have been few studies in Korea which reviewed competition law enforcement of EU competition authorities on the pharmaceutical industry. Therefore, this article reviews the recent report of the EU Commission and tries to find implications on the enforcement of MRFTA and relevant competition policy. First, regarding the antitrust enforcement, it seems that the KFTC have mainly focused on rebate issue in the pharmaceutical industry. It is time for the KFTC to review other type of violations which the EU competition authorities have regulated, such as misuse of patent system and other regulatory frameworks for preventing generic companies from entering the market, disparagement the quality or safety of generic drugs for preventing generic companies from entering the market, and the excessive pricing by the original companies. Also, regarding the merger regulation, it is necessary for the KFTC to carefully review the concerns about innovation competition in merger cases involving the industry and find the best remedies through sufficient consultation with the merging entities. For this, experiences of the EU competition authorities on the innovation competition in merger cases of pharmaceutical companies would be great helpful. Additionally, regarding the competition policy, market monitoring about the pharmaceutical industry should be carried out more regularly by the KFTC with reference to the experience of EU competition authorities. Finally, it is necessary for the KFTC to check loopholes in other regulations related to the pharmaceutical industry from the perspective of competition law through competition advocacy activities.
Abstract
Europe, together with United States, has led the growth of the pharmaceutical industry around the world. However, some criticized that principle of competition did not work well due to the structural and regulatory characteristics of the pharmaceutical industry. In 2009, the EU Commission conducted sector inquiry on the pharmaceutical industry and reviewed various legal issues in the perspective of the EU competition rules. After the sector inquiry, EU competition authorities have actively enforced their competition rules on the pharmaceutical industry and have actively prepared and implemented competition policies for the industry. Finally, at the request of the EU Parliament and the EU Council, the EU Commission recently submitted a report which includes representative cases and relevant statistics of EU competition authorities on the pharmaceutical industry. Because the industry size is very large and lots of dominant companies have been existed, violations of competition rules have been occurred in various forms and ways. In the perspective of comparative law and comparative administration, it is highly valuable to research about how the EU competition rules, which has played a major role in the global competition law with the United States, has addressed the behaviors. However, since the KFTC published the competition policy report on pharmaceutical industry in 2009, there have been few studies in Korea which reviewed competition law enforcement of EU competition authorities on the pharmaceutical industry. Therefore, this article reviews the recent report of the EU Commission and tries to find implications on the enforcement of MRFTA and relevant competition policy. First, regarding the antitrust enforcement, it seems that the KFTC have mainly focused on rebate issue in the pharmaceutical industry. It is time for the KFTC to review other type of violations which the EU competition authorities have regulated, such as misuse of patent system and other regulatory frameworks for preventing generic companies from entering the market, disparagement the quality or safety of generic drugs for preventing generic companies from entering the market, and the excessive pricing by the original companies. Also, regarding the merger regulation, it is necessary for the KFTC to carefully review the concerns about innovation competition in merger cases involving the industry and find the best remedies through sufficient consultation with the merging entities. For this, experiences of the EU competition authorities on the innovation competition in merger cases of pharmaceutical companies would be great helpful. Additionally, regarding the competition policy, market monitoring about the pharmaceutical industry should be carried out more regularly by the KFTC with reference to the experience of EU competition authorities. Finally, it is necessary for the KFTC to check loopholes in other regulations related to the pharmaceutical industry from the perspective of competition law through competition advocacy activities.
참고문헌 (51)
- Neil Lunt, "고령화시 영국 국가보건의료서비스(NHS)의 과제와 전망", 국제사회보장리뷰, 1(1), pp.7~18 (2017), 한국보건사회연구원
- EU의 경쟁법 판례분석, "공정거래위원회", ~ (2008)
- 공정거래위원회, "제약산업, 가격․품질이 아닌 판촉경쟁이 치열한 규제산업 -공정위, 제약산업 경쟁정책보고서 발간", ~ (2009)
- 공정거래위원회, "해외경쟁정책동향 제10호", ~ (2009)
- 공정거래위원회, "주요 제약사에 대한 지식재산권 관련 서면 실태조사 실시", ~ (2010)
- 국내제약산업분야에 있어서 지재권 실태분석 연구, "공정거래위원회", ~ (2017)
- 공정거래위원회, "해외경쟁정책동향, 제129호", ~ (2017)
- 공정거래위원회, "2018년 공정거래백서" (2018)
- 동태적 혁신경쟁과 경쟁법 집행에 관한 연구. 2017년도 KOFAIR 연구보고서, "권영관", 한국공정거래조정원, ~ (2017)
- 김남우, "경쟁제한적 공동행위 그리고 비방광고의 경계: 최근 유럽사법재판소의 판결 소개", 최신외국법제정보, 1(1), pp.59~69 (2018), 한국법제연구원
- 김철호, "역지급 합의에 대한 미국, EU 및 한국의 최근 결정", LAW & TECHNOLOGY, 9(5), pp.44~59 (2013), 서울대학교 기술과법센터
- 김희은, "유럽의 제약산업 관련 경쟁법 집행동향: Sector Inquiry, 역지불합의, 특허권 남용을 중심으로", 경쟁저널, 170, pp.128~139 (2013)
- 불공정거래행위 및 시장지배적지위남용행위 관련 위원회 심결정리 및 분석, "명지대학교 산학협력단", 공정거래위원회, ~ (2007)
- 박성민, "제약 산업에서의 시장 경제 원리 활성화 방안 - 정부의 역할을 통한 시장 기능 정상화, 공정거래위원회와 법원, 보건복지부의 태도를 중심으로 -", 경제법연구, 9(1), pp.245~287 (2010), 한국경제법학회[DOI]
- 이원우, "경제규제법론" (2010), 홍문사
- 최난설헌, "제약산업에서의 경쟁법에 의한 지적재산권 남용행위 규제 - EU 사례분석-", 경쟁법연구, 27, pp.96~126 (2013), 한국경쟁법학회
- 최지원, "EU 집행위원회의 전자상거래 시장에 대한 업계조사", 경쟁저널, 18, pp.128~137 (2015)
- 한국제약바이오협회, "2017 한국 제약산업 길라잡이", ~ (2017)
- 홍대식, "공정거래위원회의 경쟁주창", 상사법연구, 31(4), pp.291~325 (2013), 한국상사법학회
- Alison Jones, "EU Competition Law" (2016), Oxford University Press
- EU Council, "Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States", ~ (2016)
- EU Parliament, "Resolution of 2 March 2017 on EU options for improving access to medicines", ~ (2017)
- EU Commission, "Antitrust: Commission fines Lundbeck and other pharma companies for delaying market entry of generic medicines", ~ (2013)
- EU Commission, "Antitrust: Commission fines Johnson & Johnson and Novartis € 16 million for delaying market entry of generic pain-killer fentanyl", ~ (2013)
- EU Commission, "Antitrust: Commission welcomes improved market entry for lung disease treatments", ~ (2011)
- EU Commission, "Antitrust: Commission opens formal investigation into Aspen Pharma's pricing practices for cancer medicines", ~ (2017)
- EU Commission, "Mergers: Commission approves acquisition of Allergan Generics by Teva, subject to conditions", ~ (2016)
- EU Commission, "Mergers: Commission approves acquisition of Hospira by Pfizer, subject to conditions", ~ (2015)
- EU Commission, "Mergers: Commission approves acquisition of GSK's oncology business by Novartis, subject to conditions", ~ (2015)
- EU Commission, "Mergers: Commission approves acquisition of Actelion by Johnson & Johnson, subject to conditions", ~ (2017)
- EU merger control and innovation, "EU Commission", ~ (2016)
- EU Commission, "Antitrust: Commission opens formal investigation into Aspen Pharma's pricing practices for cancer medicines", ~ (2017)
- 8th Report on the Monitoring of Patent Settlements(period: January-December 2016), "EU Commission", ~ (2018)
- Study on the economic impact of supplementary protection certificates, pharmaceutical incentives and rewards in Europe, "EU Commission", ~ (2018)
- EU Commission, "Competition Enforcement in the Pharmaceutical Sector (2009-2017)", ~ (2019)
- Italy: Practices to delay Market Entry of Generics are anti-competitive, "European Competition Network", ECN, ~ (2012)
- United Kingdom: The Office of Fair Trading (OFT) Issues Statement of Objections for Alleged Abuse of a Dominant Position in the Pharmaceutical Sector, "European Competition Network", ECN, ~ (2010)
- France: The Autorité de la Concurrence fines Sanofi-Aventis € 40600000 for denigrating Generic Versions of branded Drug Plavix, "European Competition Network", ECN, ~ (2013)
- France: The Autorité de la concurrence fines Pharmaceutical Company Schering-Plough for impeding Arrival of Generic of its Originator Medicinal Product Subutex, "European Competition Network", ECN, ~ (2014)
- Italy: The Italian Competition Authority fines Roche and Novartis for Cartelizing Sales of two major Ophthalmic Medicines, "European Competition Network", ECN, ~ (2014)
- Competition and Markets Authority, "CMA fines pharma companies £45 million", ~ (2016)
- Competition and Markets Authority, "CMA fines Pfizer and Flynn £90 million for drug price hike to NHS", ~ (2016)
- Autorité de la Concurrence, "The Autorité de la concurrence imposes a fine of 25 million euros on Janssen-Cilag laboratory and its parent company Johnson & Johnson for having first prevented then restricted the development of generic versions of Durogesic, its originator medicinal product", ~ (2017)
- Danish Competition Council, "CD Pharma has abused its dominant position by increasing their price by 2,000 percent", ~ (2018)
- Autorità Garante della Concorrenza e del Mercato, "A480 - Price increases for cancer drugs up to 1500%: the ICA imposes a 5 million Euro fine on the multinational Aspen", ~ (2016)
- "고려대학교 ICR 센터"[URL]
- "주벨기에유럽연합대한민국대사관"[URL]
- "주오이시디대한민국대표부"[URL]
- "법률신문"[URL]
- "중앙일보"[URL]
- "그 외 공정거래위원회 연도별 통계연보 및 연도별 기업결합 주요 특징 및 동향 자료", ~